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Abstract
Weight loss is crucial for treating type 2 diabetes mellitus (T2DM). It remains unclear which dietary intervention is best for optimising
glycaemic control, or whether weight loss itself is the main reason behind observed improvements. The objective of this study was to assess
the effects of various dietary interventions on glycaemic control in overweight and obese adults with T2DM when controlling for weight loss
between dietary interventions. A systematic review of randomised controlled trials (RCT) was conducted. Electronic searches of Medline,
Embase, Cinahl and Web of Science databases were conducted. Inclusion criteria included RCT with minimum 6 months duration, with
participants having BMI≥ 25·0 kg/m2, a diagnosis of T2DM using HbA1c, and no statistically signiﬁcant difference in mean weight loss at the
end point of intervention between dietary arms. Results showed that eleven studies met the inclusion criteria. Only four RCT indicated the
beneﬁt of a particular dietary intervention over another in improving HbA1c levels, including the Mediterranean, vegan and low glycaemic
index (GI) diets. However the ﬁndings from one of the four studies showing a signiﬁcant beneﬁt are questionable because of failure to control
for diabetes medications and poor adherence to the prescribed diets. In conclusion there is currently insufﬁcient evidence to suggest that any
particular diet is superior in treating overweight and obese patients with T2DM. Although the Mediterranean, vegan and low-GI diets appear to
be promising, further research that controls for weight loss and the effects of diabetes medications in larger samples is needed.
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Dietary intake is recognised as a major contributor to both the
development and management of type 2 diabetes(1). The current
American Diabetes Association (ADA) recommendations for
overweight and obese patients with type 2 diabetes mellitus
(T2DM) include reducing energy intake while maintaining
healthful eating patterns in order to promote weight loss(2).
Different diets have been studied to determine their impact on
the management of T2DM. With regard to prevention, a recent
meta-analysis of prospective cohort studies comprising 21 372
cases demonstrated that healthy diets (e.g. Mediterranean diet,
dietary approaches to stop hypertension) were equally asso-
ciated with a 20 % decreased risk of developing T2DM(3).
However, there remains no conclusive evidence as to which
diet, if any, is the most effective in optimising glycaemic control
in patients with T2DM(4).
Two systematic reviews have examined the effects of different
dietary interventions in managing T2DM. Ajala et al.(5)
investigated the effects of low-carbohydrate, vegetarian, vegan,
low glycaemic index (GI), high-ﬁbre, Mediterranean and high-
protein diets as compared with control diets (low fat, high GI,
low protein, and diets described as following guidelines of the
ADA or European Association for the Study of Diabetes). They
concluded that the Mediterranean, low-carbohydrate, low-GI
and low-protein diets resulted in greater improvements in
HbA1c when compared with their respective controls, with the
Mediterranean diet having the greatest effect. Meta-analyses also
indicated that both the Mediterranean and low-carbohydrate
diets produced the greatest weight loss (−1·84 and −0·69 kg,
respectively).
Wheeler et al.(6) conducted a systematic review that took a
different approach. They examined the impact of macronutrients,
food groups and eating patterns on diabetes management and
risk for CVD. This was a follow-up to the literature review
published by the ADA in 2001, and thus the authors only
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included studies published from 2001 to 2010. The authors
concluded that many diets improved glycaemic control and
cardiovascular risk factors; however, no one diet was identiﬁed
as superior.
Both of these systematic reviews included studies in which
the diets being examined resulted in greater weight loss than
the respective ‘control diet’, making it difﬁcult to determine
whether the improvement in glycaemic control was due to
weight loss or due to the composition of the diet. There is a
need for a new systematic review to address this limitation.
Thus, the aim of this systematic review was to analyse the
results from only randomised controlled trials (RCT) where
different dietary interventions were compared, and in which the
total mean weight loss between groups was not statistically
signiﬁcantly different. If this analysis indicates signiﬁcant
improvements in glycaemic control, this would suggest that a
particular diet may be more optimal for diabetes management.
Methods
Criteria for study consideration: types of studies and
subjects
Only RCT with a minimum duration of 6 months and a measure
of HbA1c were considered for this review, in order to examine
long-term changes in HbA1c. The review set out to investigate
the effects of dietary interventions in overweight and obese
adults with T2DM; therefore, only studies in which subjects had
a BMI of 25·0 kg/m2 or higher, along with a conﬁrmed diagnosis
of diabetes in line with the WHO diagnostic criteria(7), were
considered for inclusion. Studies needed to have at least two
arms examining differences between dietary interventions. As
the main aim of this study was to examine the impact of various
diets on T2DM management independent of differential effects
of weight loss, only trials in which there were no statistically
signiﬁcant differences in the mean weight lost between the arms
were considered for inclusion. Studies including pharmacolo-
gical or physical activity interventions were excluded. Only
interventions using a whole-diet approach were of interest, and
hence trials involving individual foods, functional foods or
individual supplements were excluded.
Outcome measures
The main outcome of interest for this review was the mean
difference in HbA1c between dietary arms at the end point of
intervention.
Search strategy
Electronic searches were conducted in Medline, Embase, Cinahl
and Web of Science databases including all studies published as
of 29 June 2015. References of included studies along with
published reviews were hand searched for additional studies.
Individual search strategies were developed according to the
speciﬁcations of the different databases. A combination of
exploded medical subject headings (MeSH) and free text
searching was used as part of the search strategies. MeSH
headings that were used included ‘Type 2 diabetes’, ‘NIDDM’,
‘Haemoglobin A, Glycosylated’, ‘Diet’, ‘Dietary proteins’,
‘Dietary fats’, ‘Dietary carbohydrates’, ‘Glycaemic index’,
Glycaemic load’ and their variants. The search was limited
to studies written in the English language (see online
Supplementary Appendix S1).
V. W. who was our research librarian was instrumental in
working with the lead author (A. E.) to develop and ﬁnalise the
search strategy for the four databases. A. E. screened all titles
and abstracts and initially assessed studies for inclusion. Where
it was unclear whether a study met the inclusion criteria, a
second author (J. L. T.) screened the reports.
Study quality assessment and data extraction
The lead author (A. E.) rated the quality of the RCT identiﬁed
by the searches using the Joanna Briggs Institute(8)
critical appraisal tool to ensure trials were of a sufﬁcient
quality (see online Supplementary Appendix S2). A second
independent reviewer rated the quality of a sub-sample of
twenty relevant articles. Data extraction was then conducted
by A. E. and an independent reviewer on the ﬁnal eleven
articles that met all inclusion criteria, using a custom-designed
data extraction sheet.
As the published studies lacked a common control diet for
comparison, it was not possible to conduct a meta-analysis of
the results from the included studies. Thus, the results of a
qualitative synthesis are reported here.
Results
Study selection
Through initial electronic database searching and hand
searching, 705 studies were identiﬁed (Fig. 1). After removal of
duplicates, this was reduced to 525 studies. The initial stage of
assessing studies focused on excluding studies based on
information present in the titles and abstracts, which resulted in
the elimination of 540 studies. A total of twenty remaining
studies were then accessed in full text form to further assess
eligibility. Of these twenty studies, nine were excluded as they
failed to meet one or more of the inclusion criteria (Fig. 1). The
remaining eleven studies met all inclusion criteria and after
critical appraisal were deemed to meet the quality requirements
to be included in the qualitative synthesis.
Study and subject characteristics
The eleven studies included in this review are summarised in
Table 1. The duration of the interventions ranged from
40 weeks(9) to 4 years(10). The trials varied in size, with the
smallest study including forty(11) participants and the largest
study including 259(12) participants. The pooled sample size for
all studies was n 1266.
Interventions: general overview
A wide range of dietary interventions were examined,
including low-fat vegan, ADA, low GI, high-protein diet,
standard protein diet, low-fat diet, low carbohydrate, low
glycaemic load (GL), low carbohydrate Mediterranean (LCM),
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traditional Mediterranean (TM), high carbohydrate/ﬁbre and
a modiﬁed lipid diet. Of the eleven studies included, two
compared three different dietary interventions, whereas the
other nine studies compared two dietary interventions. In total
there were twenty-four individual comparators.
Interventions showing a positive effect
From the eleven studies, nine demonstrated a positive effect of
dietary intervention on improving HbA1c values at the end
point of intervention(9–17). However, ﬁve of these studies did
not report statistically signiﬁcant differences between dietary
arms in the reductions in HbA1c values(11,14–17), and hence
do not appear to support the use of one dietary intervention
over another, as comparators had similar positive effects on
glycaemic control.
Interventions showing no effect
Out of the eleven studies, two reported that the prescribed
dietary interventions failed to decrease HbA1c levels(18,19).
Guldbrand et al.(18) compared a low-carbohydrate diet with a
low-fat diet, and despite both groups experiencing signiﬁcant
weight loss there were no signiﬁcant improvements in HbA1c at
the end point of either dietary intervention. However, the
authors stated that at 6 months into the intervention there was a
statistically signiﬁcant difference in mean insulin dose in favour
of the low-carbohydrate diet (P= 0·046). Brehm et al.(19) com-
pared a predominantly MUFA diet with a high-carbohydrate
diet, and again despite reductions in body weight over
12 months of 4·0 (SD 0·8) v. 3·8 (SD 0·6) kg, respectively, the
interventions failed to be effective in improving glycaemic
control, with non-signiﬁcant mean changes in HbA1c levels for
both groups. It is important to note that authors reported a lack
of information about changes that were made to the type and
dosage of glucose-lowering medication. Therefore, it appears
that no adjustments were made to account for the effects of
medication on glycaemic control. This lack of ability to take into
consideration the effect of medication on glycaemic control is a
potential limitation.
Interventions showing signiﬁcant differences between
dietary groups
Only four studies reported a signiﬁcant difference in HbA1c
between different dietary interventions despite a non-signiﬁcant
difference in weight loss (Table 1)(9,10,12,13).
Fabricatore et al.(9) compared a low-fat diet with a low-GL
diet, with the subjects in the low-GL group experiencing a
signiﬁcantly greater reduction in HbA1c compared with those in
the low-fat diet group: 0·8 (SD 0·0104) v. 0·1 (SD 0·0012) %,
respectively (P= 0·01). Authors reported that the values pre-
sented were adjusted to account for changes in glucose-
lowering medication, and that the percentage of participants
who increased, decreased or did not change their medication
protocol was not statistically different between groups at week
20 (P= 0·51) or at week 40 (P= 0·70). Therefore, this study
appears to demonstrate a beneﬁt of a low-GL diet over a low-fat
diet in improving HbA1C levels.
699 records identified through electronic
database searching
6 additional records identified through
other sources
705 articles identified
165 duplicates removed
540 original articles
520 excluded as titles and abstracts
did not meet the inclusion criteria
20 full text articles assessed for
eligibility
• 9 full text articles excluded:
• 3 used a HbA1c > 6.0 for diagnosis 
• 3 studies included participants with BMI < 25.0 
• 1 had no measure of HbA1c
• 1 not a macronutrient-based diet
• 1 used a meal replacement
11 studies included in qualitative
synthesis
Fig. 1. Flow diagram showing the number of studies screened, assessed for eligibility, and included in the review.
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Table 1. Table summarising the results of changes in HbA1c from the eleven dietary interventions included in the systematic review
(Mean values and standard deviations for mean weight loss and mean reduction HbA1c)
HbA1c (%) at
baseline
References Participants Mean SD
Intervention
(n per arm)
Composition of
prescribed diets
Mean weight
loss (kg)
Mean decrease
in HbA1c (%) Duration Attrition rate Medication Conclusion
Guldbrand
et al.(18)
61 overweight and
obese adults with
type 2 diabetes
7·35 LFD (31) v. LCD (30) LFD: 55–60% CHO,
10–15% protein,
30% fat
LCD: 20% CHO,
30% protein,
50% fat
2·97 v. 2·34
(P= 0·33)
− 0·2 v. 0: no
significant
difference
between
groups
(P= 0·76)
2 years 9·7% in LFD group
and 13·3% in
LCD
Authors reported that at
6 months there was a
statistically significant
difference in mean insulin
dose in favour of the LCD
(P= 0·046)
No significant
difference
between dietary
interventions in
improving HbA1c
Brehm et al.(19) 124 overweight and
obese adults with
type 2 diabetes
7·3 High-MUFA diet (43)
v. HC diet (52)
MUFA: 45% CHO,
15% protein,
40% fat (20%
MUFA)
CHO: 60% CHO,
15% protein,
25% fat
4·0 (SD 0·8) v.
3·8 (SD 0·6)
(P= 0·867)
0 v. –0·1: authors
stated no
significant
difference
between
groups (no P
value reported)
12 months 31% for the MUFA
group and 16%
for the HC group
Authors reported a lack of
available information about
participant’s drug usage.
Only information on 32
participants’ drug use was
available, which showed no
systematic differences
between diet groups.
Therefore no adjustments
were made for glucose-
lowering medication
No significant
difference
between dietary
interventions in
improving HbA1c
Fabricatore
et al.(9)
79 obese adults with
type 2 diabetes
6·8 Low fat (39) v. low
GL (40)
Low fat: <30% fat
Low GL: 3 or less
servings of
moderate-GL and
1 or less serving
of high-GL foods/d
4·5 (SD 0·34)
v. 6·4 (SD
0·52)
(P= 0·28)
0·1 (SD 0·0012) v.
0·8 (SD 0·0104):
significant
difference
between
groups
(P= 0·01)
40 weeks 36·7% Authors stated that changes in
HbA1c were adjusted for
medication use. Percentage
of participants who
increased, decreased or did
not change their diabetic
medication regime did not
differ between the groups at
week 20 (P= 0·51) or at
week 40 (P= 0·70)
Low GL appears to
be more effective
in reducing HbA1c
compared with a
the LFD
Elhayany et al.(12) 259 overweight and
obese adults with
type 2 diabetes
8·3 LCMD (61) v. TM
diet (63) v. ADA
diet (55)
LCM: 35% low-GI
CHO, 15–20%
protein, 45% fat
rich in MUFA
TM: 50–55% low-GI
CHO, 15–20%
protein, 30% fat
rich in MUFA
ADA: 50–55% CHO,
15–20% protein,
30% fat
10·1 v. 7·4 v.
7·7
authors
stated no
significant
difference
between
groups (no
P value
reported)
2·0 v. 1·8 v. 1·6
significant
difference
between diets
(P= 0·021),
LCM different
than ADA, TMD
different than
ADA
12 months 30·9% Authors do not mention
baseline medication
characteristics or any
changes in glucose-
lowering medication use
during the course of the
intervention
LCM diet appears to
be more effective
in reducing HbA1c
compared with a
TM and ADA diets
Barnard et al.(13) 99 obese adults with
type 2 diabetes
7·99 Low-fat vegan diet
(49) v. ADA diet
(50)
Low-fat vegan diet:
75% CHO, 15%
protein, 10% fat
ADA: 60–70% CHO,
15–20% protein
and MUFA
4·4 (SD 0·9) v.
3·0 (SD 0·8)
(P= 0·25)
0·34(SD 0·19) v.
0·14 (SD 0·17)
no significant
difference
between
groups
(P= 0·43) 0·4%
v. 0·01%
(P= 0·03) when
adjusted for
medication
74 weeks 18·4% for the vegan
group 14% for
the ADA group
Net 74-week dosages were
reduced in 35%
participants in vegan group
and 20% of those in the
ADA group, and were
increased in 14% of vegan
group and 24% of
conventional group
Once data are
adjusted for
medication use,
there appears to
be a significant
benefit in the low-
fat vegan diet in
decreasing HbA1c
compared with the
ADA diet
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Table 1 Continued
HbA1c (%) at
baseline
References Participants Mean SD
Intervention
(n per arm)
Composition of
prescribed diets
Mean weight
loss (kg)
Mean decrease
in HbA1c (%) Duration Attrition rate Medication Conclusion
Esposito et al.(10) 215 overweight adults
with type 2 diabetes
7·73 LCMD (107) v. LFD
(108)
LCMD: 50% CHO,
20% protein, no
<30% fat
LFD: no >30% fat
with no >10%
SFA
3·8 (SD 2) v.
3·2 (SD 1·9)
authors
stated no
significant
difference
between
groups (no
P value
reported)
0·9 (SD 0·6) v. 0·5
(SD 0·4) authors
stated
significant
differences
between
groups (no
P value
reported)
4 years 9·3% After 4 years 44% of
participants in the LCMD
and 70% of those in the
LFD group required
treatment (absolute
difference, −26·0
percentage points (95% CI
0·51, 0·86), hazard ratio
adjusted for weight change,
0·70 (95% CI 0·59, 0·90);
P< 0·001).
LCMD appears to be
more effective in
reducing HbA1c
compared with a
LFD with less
need for glucose-
lowering
medication
Pedersen et al.(14) 76 overweight adults
with type 2 diabetes
7·3 HPD (21) v.
standard protein
diet (24)
HPD: 40% CHO,
30% protein,
30% fat
SPD: 50% CHO,
20% protein,
30% fat
9·7 (SD 2·9) v.
6·6 (SD 1·4)
(P= 0·32)
0·4 v. 0·3 no
significant
difference
between
groups
(P= 0·29)
12 months 40·8% Did not account for changes in
medication, although
authors stated that 4
volunteers managed their
diabetes with diet alone,
and all others treated with
oral medication and/or
insulin
No significant
difference
between dietary
interventions in
improving HbA1c
Iqbal et al.(17) 144 obese adults with
type 2 diabetes
7·75 LCD (40) v. LFD (28) Low CHO: <30 g/d
CHO
Low fat: ≤30% of
energy for fat with
<7% of energy
from SFA
1·5 v. 0·2
(P= 0·147)
0·1 v. 0·2 no
significant
difference
between
groups (no
P value
reported)
24 months 60% in the low-CHO
group and 46% in
the low-fat group
Authors stated that many
participants were unable to
provide information
regarding changes to
medication or dosages and
therefore the effects of
glucose-lowering
medication was not
adjusted for
No significant
difference
between dietary
interventions in
improving HbA1c
Ma et al.(11) 40 overweight and
obese adults with
type 2 diabetes
8·42 ADA diet (21) v. low-
GI diet (19)
ADA: 60–70% CHO,
15–20% protein
and 30% fats
Low GI: participants
given goals to
reduce daily
dietary GI score
to 55
0·80 v. 1·32
(P= 0·89)
0·43 v. 0·35 no
significant
difference
between
groups
(P= 0·88)
12 months 10% for the ADA
group and 10%
for the low-GI
group
Participants in the low-GI
group were less likely to
add or increase dosage of
glucose-lowering
medications (OR 0·26;
P= 0·01)
No significant
difference
between dietary
interventions in
improving HbA1c
Milne et al.(15) 70 overweight and
obese adults with
type 2 diabetes
10·0 0·35 Weight management
diet (21) v. HC/
fibre diet (21) v.
modified lipid diet
(22)
Weight management
diet: restrict
extrinsic simple
sugars and
energy dense
foods, no advice
for macronutrient
contribution
HC/fibre: 55% CHO,
15% protein,
30% fat, 30 g or
more dietary
fibre/d
Modified lipid diet:
45% CHO, 19%
protein, 36% fat
− 1·5 v. 1·0 v.
0·1
authors
stated no
significant
difference
between
groups (no
P value
reported)
0·1 v. 0·1 v. 0·2
authors stated
no significant
difference
between
groups (no
P value
reported)
18 months 8·6% Authors state that 52·3% of
the weight management
group, 57·1% of the HC/
fibre group and 50% of the
modified lipid diet were on
glucose-lowering
medication at baseline.
However there is no
mention of medication
adjustments being made
throughout the study
No significant
difference
between dietary
interventions in
improving HbA1c
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Table 1 Continued
HbA1c (%) at
baseline
References Participants Mean SD
Intervention
(n per arm)
Composition of
prescribed diets
Mean weight
loss (kg)
Mean decrease
in HbA1c (%) Duration Attrition rate Medication Conclusion
Larsen et al.(16) 99 overweight and
obese adults with
type 2 diabetes
7·84 HPD (53) v. HC diet
(46)
HP: 40% CHO,
30% protein,
30% fat
HC: 55% CHO,
15% protein,
30% fat
2·23 v. 2·17
(P= 0·78)
0·23 v. 0·28 no
significant
difference
between
groups
(P= 0·44)
12 months 9·2% HP group v.
4·2% HC
Authors reported a significant
reduction in the requirement
for glucose-lowering
medication in the HP group
compared with the HC
group at 3 months
(P= 0·03) although the
difference was no longer
significant at 12 months
(P= 0·05). However authors
stated that that there were
not significant differences in
the decrease in HbA1c
between groups when
values were adjusted for
changes in medication
No significant
difference
between dietary
interventions in
improving HbA1c
LFD, low-fat diet; LCD, low carbohydrate diet; CHO, carbohydrate; HC, high carbohydrate; low GL, low glycaemic load; LCMD, low carbohydrate Mediterranean diet; TM, traditional Mediterranean; ADA, American Diabetes Association;
LCM, low carbohydrate Mediterranean; GI, glycaemic index; TMD, traditional Mediterranean diet; HPD, high-protein diet; SPD, standard protein diet; HP, high protein.
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Elhayany et al.(12) conducted a three-arm intervention com-
paring a LCM diet, a TM diet and the 2003 ADA diet. All three
interventions were successful in reducing weight and improving
HbA1c levels. Subjects in the LCM diet experienced the greatest
reduction in HbA1c: 2·0 % compared with 1·8 % in the TM
group and 1·6 % in the ADA group (P= 0·021). However, it is
important to view these results with caution, as authors do not
report baseline medication characteristics of the participants or
any changes in glucose-lowering medication throughout the
course of the intervention. Therefore, values have not been
adjusted for medication, and the lack of information available
regarding type and dosage of glucose-lowering medication
makes it impossible to conﬁrm that it was the LCM diet itself that
was more effective in reducing HbA1c, or whether the changes
observed may have been a result of differences in medication
use and dosage between the three intervention groups.
Barnard et al.(13) compared a low-fat vegan diet with an ADA
diet, with results showing a greater mean reduction in HbA1c
for patients on the low-fat vegan diet. Authors reported a mean
decrease of 0·4 % for the low-fat vegan group and 0·1 %
decrease for the ADA group once adjustments were made for
changes in medication.
Esposito et al.(10) compared an LCM diet with a low-fat diet.
The LCM diet led to a signiﬁcantly greater reduction in Hba1c,
with a mean decrease of 0·9 % compared with the 0·5 %
achieved in the low-fat diet group. This study appears to show a
beneﬁt of using an LCM diet over a low-fat diet in reducing
Hba1C levels beyond the effects of weight loss. Two of the
strengths of this study are that all participants were newly
diagnosed with T2DM and were not taking any form of glucose-
lowering medication. The primary outcome of the study was
commencement of medication, which itself followed a strict
protocol. As shown in Table 1, the LCM diet resulted in a
signiﬁcantly lower HbA1c value with less need for glucose-
lowering medication when compared with the low-fat diet
(LFD). However, because of the nature of the study design,
physicians were not blinded to the intervention groups in order
to administer medication, which is a limitation.
Limitations in adherence to prescribed diets
One issue common to most studies was the lack of compliance
to the prescribed dietary intervention. As shown in Table 2,
apart from Pedersen et al.(14) who used the 24-h urea excretion
method for assessing adherence to prescribed protein intakes,
the remaining ten studies relied on self-report dietary intake
data. Differences in prescribed v. reported diets are apparent
when comparisons are made with the macronutrient targets set
at baseline to those that were reported at the end point of
intervention (Table 2). Pedersen et al.(14) reported that adjusted
urea excretion was signiﬁcantly different between groups (519
(SD 39) for the high-protein diet and 456 (SD 25) for the standard
protein diet group; P= 0·04), indicating compliance to the
protein prescription. In contrast, Iqbal et al.(17) reported no
signiﬁcant difference in macronutrient intake between groups at
any point during the intervention. In this study the subjects in
the low-carbohydrate group were prescribed a diet with <30 g
of carbohydrates/d; however, data from 3-d food diaries
revealed a mean carbohydrate intake of 192·8 g/d. Similarly,
Barnard et al.(13) reported that, at the end point of intervention,
dietary adherence was met by only 51 % of those in the low-fat
vegan group and by 48 % of those in the ADA group.
Discussion
The results of this systematic review indicate that only four out
of the eleven trials demonstrated a beneﬁt of one particular
dietary intervention over another. These diets were low GL,
LCM and low-fat vegan. Therefore, it appears that these diets
may have a beneﬁcial effect on HbA1c independent of weight
loss. However, there are two major limitations within most of
these studies that could have substantially affected the reported
results: lack of reporting and controlling for medication use and
change, and poor compliance to the dietary intervention being
studied.
Elhayany et al.(12) demonstrated that the low carbohydrate
Mediterranean diet (LCMD) was more effective than the TMD
and the ADA diet in reducing HbA1c. However, this study
lacked any control over the effects of glucose-lowering
medication, with no information available about baseline
medication or any changes to medication occurring during the
trial. Therefore, we cannot be certain whether the effects on the
outcome measures were due to the dietary intervention or due
to effects of glucose-lowering medication.
The three interventions that show promise appear to be those
of Fabricatore et al.(9), who demonstrated the beneﬁt of a low-
GL diet over a low-fat diet, Barnard et al.(13) who demonstrated
a potential beneﬁt of a low-fat vegan diet compared with the
ADA diet, and Esposito et al.(10) who showed a beneﬁt of using
an LCM diet over a low-fat diet. In contrast to the study by
Elhayany et al.(12) these three studies reported how changes in
glucose-lowering medication were managed and accounted for
throughout the interventions. Furthermore, both Barnard
et al.(13) and Esposito et al.(10) reported that HbA1c values were
signiﬁcantly reduced, with less need for glucose-lowering
medication in the low-fat vegan and LCM dietary groups. Fab-
ricatore et al.(9) demonstrated a beneﬁt of using a low-GL diet
compared with a low-fat diet; however, a limitation of this
intervention was the high attrition rate of 36·7 %.
Although the mechanisms leading to enhanced glycaemic
control in these studies were not examined, existing research
may help explain their ﬁndings. One potential mechanism for
the effectiveness of a low-fat vegan diet is its high dietary ﬁbre
content. By the end of the 74-week intervention, subjects in the
low-fat vegan group were consuming a signiﬁcantly greater
amount of dietary ﬁbre than were those in the ADA group (21·7
(SD 1·2) v. 13·4 (SD 0·8) g/4184 kJ (1000 kcal)). Both Post et al.(20)
and Silva et al.(21) conducted meta-analyses demonstrating the
beneﬁts of increasing ﬁbre intakes and improved glycaemic
control in patients with T2DM. Although these meta-analyses
did not control for energy consumption, they do highlight the
importance of dietary ﬁbre in diabetes management. This is of
importance when considering the effects of dietary approaches
such as low-fat vegan or Mediterranean diets, as dietary ﬁbre
intakes tend to increase when consuming these diets, and as
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Table 2. Table summarising the changes in dietary intake at baseline and at end point of intervention
References
Intervention
(n per arm)
Dietary
assessment tool
used Composition of prescribed diet Composition of diet consumed* Comments
Guldbrand
et al.(18)
LFD (31) v. LCD (30) 3-d food record LFD: 55–60% CHO, 10–15% protein,
30% fat
LFD: 47% CHO, 20% protein,
31% fat
There was a significant between group differences for the
percentage of energy from CHO, fat (P<0·001) and for
protein (P= 0·009)
LCD: 20% CHO, 30% protein, 50% fat LCD: 31% CHO, 24% protein,
44% fat
Brehm et al.(19) High-MUFA diet (43)
v. high-CHO (CHO)
diet (52)
3-d food record MUFA: 45% CHO, 15% protein, 40%
fat (20% MUFA)
MUFA: 46% CHO, 16% protein,
38% fat (20% MUFA)
The high-MUFA-diet group consumed significantly more total
fat, PUFA and MUFA than the high-CHO group (P< 0·001)
CHO: 60% CHO, 15% protein, 25% fat CHO: 54% CHO, 18% protein,
28% fat
Fabricatore
et al.(9)
Low fat (39) v. low GL
(40)
3-d food record Low fat: <30% fat Low fat: 32·9% fat GL 121·3 Reductions in energy from fat were significantly greater among
those in the low-fat group at week 40 (P≤0·01)
Low GL: 3 or less servings of moderate-
GL and 1 or less serving of high-GL
foods/d
Low GL: 39·8% fat GL 88·6 Low-GL group had significantly greater reductions in energy
from CHO (P≤0·01) and significantly greater reductions in
dietary GI (P≤0·003) and GL (P≤ 0·03)
Changes on other measured dietary variable were not
significantly different between groups
Elhayany et al.(12) LCM (61) v. TM (63)
v. ADA diet (55)
FFQ and 24-h
recall
LCM: 35% low-GI CHO, 15–20%
protein, 45% fat rich in MUFA
No breakdown of the actual
macronutrient content which
was consumed during the
intervention
Statistically significant trend in percentage of energy from PUFA
intake, highest 12·9% for LCM, to 11·5% in TM, and lowest in
ADA 11·2% (P=0·002)
TM: 50–55% low-GI CHO, 15–20%
protein, 30% fat rich in MUFA
Same significant trend observed for MUFA fat intake (14·6, 12·8,
and 12·6% for LCM, TM and ADA, respectively, P<0·001).
ADA: 50–55% CHO, 15–20% protein,
30% fat
Opposite trend seen for % of energy from CHO, highest for ADA
45·4% then 45·2% for TM and lowest for the LCM with
41·9% (P= 0·011)
Barnard et al.(13) Low-fat vegan diet
(49) v. ADA diet
(50)
3-d food record Low-fat vegan diet: 75% CHO, 15%
protein, 10% fat
Low-fat vegan diet: 66·3% CHO,
14·8% protein, 22·3% fat
At the end point of intervention, dietary adherence was met by
51% of participants in the vegan group and 48% of those in
the ADA group
ADA: 60–70% CHO, 15–20% protein
and 30% fats
ADA: 46·5% CHO, 21·14%
protein and 33·7%
Esposito et al.(10) LCMD (107) v. LFD
(108)
Food diary
records
LCMD: 50% CHO, 20% protein, no
<30% fat
LCMD: 44·2% CHO, 18%
protein, 39·1% fat, 10% SFA,
17·6% MUFA
Between group differences in % CHO and MUFA significantly
different throughout the trial
LFD: no >30% fat with no >10% SFA LFD: 51·8% CHO, 17·9%
protein, 29·4% fat, 9·4% SFA,
12·4% MUFA
Pedersen et al.(14) HPD (21) v. SPD (24) FFQ and 24 h
urea excretion
HPD: 40% CHO, 30% protein, 30% fat HPD: 39·2% CHO, 26% protein,
34·8% fat
At 12 months adjusted urea excretion was significantly different
between groups (519 (SD 39) for HPD and 456 (SD 25) for the
SPD group, P=0·04) indicating compliance to protein
prescription
SPD: 50% CHO, 20% protein, 30% fat SPD: 44·8% CHO, 21·1%
protein, 34·0% fat
Iqbal et al.(17) LCD (40) v. LFD (28) 3-d food record LCD: < 30 g/d CHO LCD: 192·8 g/d CHO Authors concluded that macronutrient intake was not
significantly different between groups at any point.
Authors concluded that both groups failed to achieve dietary
targets
Low fat: ≤30% of energy for fat with
<7% of energy from SFA
Low fat: 33·6% of energy from
fat
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Table 2 Continued
References
Intervention
(n per arm)
Dietary
assessment tool
used Composition of prescribed diet Composition of diet consumed* Comments
Ma et al.(11) ADA diet (21) v. low-
GI diet (19)
7-d dietary recall ADA: 60–70% CHO, 15–20% protein
and 30% fats
ADA: 38% CHO, 80 GI, 20%
protein, 43% fat
Differences in dietary GI did not reach significance until
12 months (P= 0·07), however GL was significantly lower in
the low-GI diet at 6 months (97 v. 141; P=0·02)
Low GI: participants given goals to
reduce daily dietary GI score to 55
Low GI: daily GI score of 76 37%
CHO, 76 GI, 20% protein,
43% fat
Milne et al.(15) Weight management
diet (21) v. high-
CHO/fibre diet (21)
v. modified lipid
diet (22)
24-h recall Weight management diet: restrict
extrinsic simple sugars and energy
dense foods, no advice for
macronutrient contribution
Weight management diet:
47·6% CHO, 18·8%, 33·6%,
17·3 g dietary fibre/d
Authors concluded that almost none of the participants
succeeded in achieving currently recommended intakes of
either CHO or unsaturated fat
High CHO/fibre: 55% CHO, 15%
protein, 30% fat, 30 g or more dietary
fibre/d
High CHO/fibre: 46·6% CHO,
21·0% protein, 32·4% fat,
21·1 dietary fibre/d
Modified lipid diet: 45% CHO, 19%
protein, 36% fat
Modified lipid diet: 46·4% CHO,
19·7% protein, 33·9% fat
Larsen et al.(16) HPD (53) v. high-
CHO diet (46)
3-d food record HPD: 40% CHO, 30% protein, 30% fat HPD: 41·8% CHO, 26·5%
protein, 30·7% fat
Significant differences between groups in the quantities of CHO
and protein consumed
High CHO: 55% CHO, 15% protein,
30% fat
High CHO: 48·2% CHO, 18·9%
protein, 32·0% fat
LFD, low-fat diet; LCD, low carbohydrate diet; CHO, carbohydrate; low GL, low glycaemic load; GI, glycaemic index; LCM, low carbohydrate Mediterranean; TM, traditional Mediterranean; ADA, American Diabetes Association; LCMD, low
carbohydrate Mediterranean diet; HPD, high-protein diet; SPD, standard protein diet.
* Values are from reported dietary intakes at the end point of intervention.
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such any observed beneﬁts on glycaemic control may
potentially be due to increased ﬁbre consumption.
A component of the Mediterranean diet that has been
highlighted as a possible mechanism for its beneﬁt in optimising
glycaemic control is the increased intake of MUFA. Esposito
et al.(10) reported a signiﬁcant increase in the percentage of
energy from MUFA in participants consuming the LCMD
compared with the LFD. Paniagua et al.(22) conducted a
prospective crossover study on eleven insulin-resistant subjects,
each spending 28 d consuming a diet high in SFA, a diet high in
MUFA and a diet high in carbohydrates. The MUFA-rich diet
improved insulin sensitivity, and lowered insulin resistance
(homoeostasis model assessment-insulin resistance) to a greater
extent compared with the high-SFA and the high-carbohydrate
diets (2·32 (SD 0·3), 2·74 (SD 0·4), 2·52 (SD 0·4), respectively,
P< 0·01). The high-MUFA diet also increased glucagon-like
peptide-1 (GLP-1) more than did the carbohydrate-rich diet.
The diets were designed to ensure weight maintenance, with no
changes in patients’ body weights reported. Therefore, this
study demonstrated a potential effect of MUFA in improving
insulin sensitivity, possibly through increased GLP-1 levels,
independent of weight change.
The current systematic review does not fully support
the ﬁndings of the previous systematic review conducted
by Ajala et al.(5), as our ﬁndings do not support any beneﬁt
of consuming low-carbohydrate or high-protein diets
over another dietary intervention. Similar to the results
of Ajala et al.(5), our ﬁndings suggest a potential beneﬁt of
a Mediterranean-style diet. Three trials were included in
their analysis, two of which were included in the current
systematic review (Elhayany et al.(12), Esposito et al.(10)), with
the third (Toobert et al (23)) not meeting the inclusion criteria of
the current systematic review as weight loss between
groups was statistically signiﬁcantly different. In addition, it
is important to note that in the study by Toobert et al.(23)
participants randomised to the Mediterranean Lifestyle
Program were not only given dietary advice to follow a Medi-
terranean diet but were also given stress management classes,
with exercise prescriptions involving both aerobic and
strength-training activity. Therefore, the beneﬁcial effects on
HbA1c could have been due to many components of the
intervention and not just dietary change. Therefore, considering
this study, along with those of Esposito et al.(10) and Elhayany
et al.(12) (who did not take into account changes in medication),
makes it difﬁcult to assess the potential use of the meta-analysis
conducted by Ajala et al.(5) in determining whether the Medi-
terranean diet is in fact superior to other dietary interventions.
Another limitation observed in the trials included in the
current review was the variations in dietary compliance (see
Table 2). The diet that was initially prescribed was not always
consistent with what was consumed by the participants. Most
studies did, however, manage to create sufﬁcient differences in
the consumption of certain macronutrients to allow researchers
to distinguish signiﬁcant differences between the dietary arms.
Other researchers, such as Iqbal et al.(17), reported that there
were no signiﬁcant differences between macronutrient intakes
at any point during the trial, and thus it is not surprising that
there was no difference in HbA1c levels between the groups.
Even though weight loss was not signiﬁcantly different
between the treatment arms in the included studies, there was a
moderate positive correlation between weight loss and HbA1c
(data not shown), indicating that higher weight loss was
associated with greater improvements in HbA1c. This ﬁnding is
not surprising, as weight loss is recognised as an integral
component of treating patients with T2DM(24).
The main strength of this systematic review is that, to our
knowledge, it is the ﬁrst to attempt to control for the effects of
weight loss between dietary treatment arms. An additional
strength of this review was the use of a recognised tool for
assessing the quality of the trials included. A limitation of our
review was that, because of the lack of a consistent control diet
in the studies examined, we were not able to conduct a meta-
analysis or provide quantitative data on the effect of the pre-
scribed diets on changes in HbA1c. It is also not clear whether
the participants included in the trials are generally representa-
tive of adults with T2DM.
In order to determine whether one particular diet is
superior in optimising glycaemic control, a number of research
design issues need to be applied in future research studies.
First, because of the nature of the effect of weight loss on
glycaemic control, it is important to control for this in
intervention studies. A well-designed study would include a
comparison of dietary interventions that are isoenergetic,
and would measure and attempt to balance the energy
expenditure of participants. If dietary arms are not isoenergetic,
it becomes difﬁcult to distinguish the effects of different
macronutrient compositions from the effects of a total energy
reduction. Another issue is the need to report medication use
and dosage, and ideally control for changes in medication.
From the eleven studies included in the current systematic
review, only six reported some account of effects of medication.
Of these, only Barnard et al.(13) and Esposito et al.(10) listed the
protocols used for how changes in medication were handled.
The effects of glucose-lowering medication are clearly of major
importance, and if the type and amounts that patients are taking
are not controlled for, then the effects of dietary interventions
on outcome measures can only be speculative. If more trials
address these limitations, it should become clearer whether
there is in fact a particular diet that is superior for treating
overweight and obese patients with T2DM.
We conclude that there is currently insufﬁcient evidence to
state that a particular diet is superior to another for treating
overweight and obese adults with T2DM. In line with current
ADA guidelines, reducing total energy intake to promote weight
loss should be the main strategy. As yet there still is not enough
evidence to promote an ideal percentage of energy from
carbohydrates, protein and fat. Although the Mediterranean,
vegan and low-GI diets appear to be promising, further
research that controls for weight loss and the effects of diabetes
medications in larger samples is needed.
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